{
    "title": "CureVac's COVID-19 vaccine triggers immune response in Phase I trial",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8905323/CureVacs-COVID-19-vaccine-triggers-immune-response-Phase-I-trial.html",
    "date": "2020-11-02",
    "keywords": [
        "vaccine",
        "trial",
        "covid19",
        "biotech",
        "mass",
        "year",
        "phase",
        "biontech",
        "shot",
        "response",
        "pandemic",
        "moderna",
        "pfizer",
        "curevac",
        "coronavirus",
        "antibody",
        "frankfurt",
        "monday",
        "company",
        "track",
        "race",
        "officer",
        "franzwerner",
        "haas",
        "statement",
        "firm",
        "messenger",
        "rna",
        "mrna",
        "partner",
        "july",
        "cvncov",
        "companys",
        "stage",
        "end",
        "investor",
        "dietmar",
        "foundation",
        "glaxosmithkline",
        "level",
        "par",
        "case",
        "university",
        "oxford",
        "candidate",
        "virus",
        "body",
        "immunisation",
        "effect",
        "anthony",
        "thursday",
        "december",
        "curevacs",
        "concentration",
        "latestage",
        "efficacy",
        "month",
        "microgramme",
        "exchange",
        "august",
        "study",
        "germany",
        "belgium",
        "inoculation",
        "indicator",
        "immune",
        "system",
        "analysis",
        "injection",
        "fatigue",
        "headache",
        "muscle",
        "pain",
        "extent",
        "reporting",
        "burger",
        "david",
        "clarke"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}